PubRank

Maria De Santis

Author PubWeight™ 38.83‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. Eur Urol 2011 5.59
2 The updated EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol 2009 2.92
3 Randomized phase III study comparing paclitaxel-bleomycin, etoposide, and cisplatin (BEP) to standard BEP in intermediate-prognosis germ-cell cancer: intergroup study EORTC 30983. J Clin Oncol 2012 2.36
4 European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I. Eur Urol 2007 2.21
5 Solitary and multiple isolated metastases of clear cell renal carcinoma to the pancreas: an indication for pancreatic surgery. Ann Surg Oncol 2006 1.95
6 Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. J Clin Oncol 2012 1.76
7 FDG PET is superior to CT in the prediction of viable tumour in post-chemotherapy seminoma residuals. Eur J Radiol 2005 1.70
8 European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II. Eur Urol 2007 1.37
9 EAU guidelines on primary urethral carcinoma. Eur Urol 2013 1.22
10 B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial. Arthritis Res Ther 2010 1.09
11 Liver involvement in subjects with rheumatic disease. Arthritis Res Ther 2011 0.98
12 Synovial fluid-derived T helper 17 cells correlate with inflammatory activity in arthritis, irrespectively of diagnosis. Clin Immunol 2010 0.96
13 IL-1B and IL-1RN gene polymorphisms in rheumatoid arthritis: relationship with protein plasma levels and response to therapy. Pharmacogenomics 2006 0.92
14 Skin ulcers in systemic sclerosis: determinants of presence and predictive factors of healing. J Am Acad Dermatol 2009 0.92
15 Modeling the ternary complex TCR-Vbeta/CollagenII(261-273)/HLA-DR4 associated with rheumatoid arthritis. PLoS One 2010 0.89
16 Collagen-specific T-cell repertoire in blood and synovial fluid varies with disease activity in early rheumatoid arthritis. Arthritis Res Ther 2008 0.86
17 Proteome analysis of biological fluids from autoimmune-rheumatological disorders. Proteomics Clin Appl 2011 0.85
18 Proteomic approaches to Sjögren's syndrome: a clue to interpret the pathophysiology and organ involvement of the disease. Autoimmun Rev 2010 0.85
19 Synovial B cells of rheumatoid arthritis express ZAP-70 which increases the survival and correlates with the inflammatory and autoimmune phenotype. Clin Immunol 2009 0.85
20 Interdisciplinary evidence-based recommendations for the follow-up of testicular cancer patients: a joint effort. Swiss Med Wkly 2010 0.83
21 Targeted treatment of metastatic castration-resistant prostate cancer with sipuleucel-T immunotherapy. Cancer Immunol Immunother 2015 0.82
22 Infectious agents and xenobiotics in the etiology of primary biliary cirrhosis. Dis Markers 2010 0.80
23 Brief report: successful pregnancies but a higher risk of preterm births in patients with systemic sclerosis: an Italian multicenter study. Arthritis Rheum 2011 0.80
24 Cell cycle dysregulation influences survival in high risk breast cancer patients. Cancer Invest 2008 0.79
25 [Chemotherapy for prostate cancer]. Wien Klin Wochenschr 2008 0.79
26 Vinflunine in the treatment of bladder cancer. Ther Clin Risk Manag 2008 0.78
27 Lupus anticoagulant and ischemic myocardial microangiopathy in rheumatoid arthritis. Nat Clin Pract Cardiovasc Med 2006 0.77
28 The autoinflammatory side of systemic sclerosis. Isr Med Assoc J 2015 0.77
29 Immunotherapies for bladder cancer: a new hope. Curr Opin Urol 2015 0.77
30 Tumor necrosis factor-alpha inhibitor therapy in erosive polyarthritis secondary to systemic sclerosis. Ann Intern Med 2005 0.76
31 Implementing newer agents for the management of castrate-resistant prostate cancer: what is known and what is needed? BJU Int 2014 0.76
32 Reply to Santhanam Sundar's letter to the editor Re: Arnulf Stenzl, Nigel C. Cowan, Maria De Santis, et al. Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. Eur Urol 2011;59:1009-18. Eur Urol 2012 0.75
33 The sword of Damocles and the treatment of stage I seminoma. J Clin Oncol 2006 0.75
34 Innovative mouse model for postchemotherapy fertility evaluation. J Androl 2005 0.75
35 [Therapy of castration-resistant prostate cancer]. Wien Klin Wochenschr 2012 0.75
36 Interdisciplinary evidence-based recommendations for the follow-up of testicular germ cell cancer patients. Onkologie 2011 0.75
37 Interdisciplinary evidence-based recommendations for the follow-up of early stage seminomatous testicular germ cell cancer patients. Strahlenther Onkol 2011 0.75
38 Splenosis peritonei. Br J Haematol 2003 0.75
39 Pharmacogenetics/pharmacogenomics and antirheumatic drugs in rheumatology. Pharmacogenomics 2004 0.75
40 Second-line therapy in bladder cancer. Curr Opin Urol 2009 0.75
41 B cell depletion and a T cell-targeted therapy allows to control the sudden onset of diabetes and lupus, without steroids. Acta Diabetol 2008 0.75